A Sept. 22 lead plaintiff deadline looms for investors in PROCEPT BioRobotics (NASDAQ: PRCT) who bought shares during a two-year window ending Feb. 25, 2026, when the company revealed its handpiece sales had outpaced actual procedures by over 10,000 units. The stock dropped more than 18 percent on that disclosure, triggering the securities fraud case.
A securities class action filed against PROCEPT BioRobotics alleges undisclosed bulk discounts inflated handpiece sales, leaving customers with more than 10,000 excess units.
"We're focused on whether PROCEPT may have intentionally pulled-in sales from future quarters to make it seem like the company was meeting expectations and, if so, whether the company had been sufficiently transparent in its investor communications," Reed Kathrein, partner at Hagens Berman Sobol Shapiro, said.
The lawsuit, Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, No. 26-cv-07691, is pending in the U.S. District Court for the Northern District of California. It covers investors who bought PROCEPT shares between Feb. 28, 2024 and Feb. 25, 2026. The complaint alleges management repeatedly touted growth in sales of the single-use handpiece, a component of the company's Aquablation therapy for enlarged prostate, while failing to disclose that an extensive discount program incentivized customers to place bulk orders exceeding procedure demand.
PROCEPT shares fell from $27.84 on Feb. 25 to $22.69 on Feb. 27, a decline of more than 18 percent on above-average volume. The company disclosed cumulative excess field inventory exceeding 10,000 handpiece units and U.S. handpiece sales sequentially falling nearly 30 percent, from 13,225 units in Q3 to 9,400 units in Q4 2025. Management said it was eliminating the previously undisclosed bulk order discount program, which incentivized customers to make large purchases during the final weeks of every quarter.
The revelations emerged through a series of partial disclosures. On Aug. 6, 2025, PROCEPT reported Q2 results showing handpiece sales missing consensus estimates by a wide margin. On Nov. 4, 2025, the company again missed expected handpiece unit sales and slashed annual guidance to allow for "optimization of field inventory," with management acknowledging it had not "been managing customer inventory" and that some customers were "probably carrying too much." By Feb. 25, 2026, PROCEPT shares had declined $22.06, or over 48 percent, from the Aug. 6, 2025 close.
The company missed its annual revenue guidance by tens of millions of dollars. Kahn Swick & Foti and Glancy Prongay Wolke & Rotter have also issued investor alerts for the case, with the Sept. 22 lead plaintiff deadline approaching. The SEC whistleblower program offers rewards of up to 30 percent of successful recoveries for individuals with non-public information about the company's practices.
The class action raises questions about revenue recognition practices across the medical device sector, where recurring consumable sales are a key growth metric. Investors will watch whether the SEC opens an investigation into PROCEPT's sales practices and whether the company revises its disclosure framework around field inventory and procedure data.
This article is for informational purposes only and does not constitute investment advice.
